PrestigeBrands

MONISTAT GOODYS ECO beano Debrox ECO Dramamme Company Noc Review of Fourth Quarter and Full Year FY 15 Results May 14, 2015

Safe Harbor Disclosure

This presentation contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements about the Company's product expansion and development plans, investments in brand building and marketing, debt reduction and future financing capacity, consumption growth and market position of the Company's brands, M&A strategy and market activity, future financial performance, and creation of shareholder value. Words such as "continue," "will," "expect," "project," "anticipate," "likely," "estimate," "may," "should," "could," "would," and similar expressions identify forward-looking statements. Such forward-looking statements represent the Company's expectations and beliefs and involve a number of known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from those expressed or implied by such forward-looking statements. These factors include, among others, the inability to identify and consummate future acquisitions at attractive valuations, the failure to successfully commercialize new products, the severity of the cold and flu season, the inability of third party suppliers to meet demand, competitive pressures, the effectiveness of the Company's brand building and marketing investments, fluctuating foreign exchange rates, and other risks set forth in Part I, Item 1A. Risk Factors in the Company's Annual Report on Form 10-K for the year ended March 31, 2014 and in Part II, Item 1A. Risk Factors in the Company's Quarterly Report on Form 10-Q for the guarter ended December 31, 2014. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date this presentation. Except to the extent required by applicable law, the Company undertakes no obligation to update any forward-looking statement contained in this presentation, whether as a result of new information, future events, or otherwise.



Agenda for Today's Discussion

- I. Fourth Quarter FY 15 Performance Highlights
- **II. FY 15 Year in Review**
- **III. Financial Overview**
- **IV. FY 16 Outlook and the Road Ahead**







Fourth Quarter FY 15 Performance Highlights

- Q4 consolidated Revenue of \$190.0 million, up 32.9% versus PY Q4
 - Organic growth of +2.4%⁽¹⁾ on a constant currency basis, and +1.1% on a reported basis versus PY Q4
- Core OTC consumption growth of +7.0% (ex. PediaCare), and +3.3% (total Core OTC)
 - 84% of Core OTC portfolio with consumption growth
- Adjusted Gross Margin of 57.9%⁽²⁾ versus 55.1% in the PY Q4, and up from 57.2% in Q3
- Adjusted EPS of \$0.47⁽²⁾, up 34.3% versus the PY Q4
- Strong Adjusted Free Cash Flow of \$50.1⁽²⁾ million, up 45.0% versus the PY Q4
 - Leverage of ~5.2x⁽³⁾, down from 5.7x at the time of Insight acquisition
- Consistent and innovative marketing support building long-term brand equity in core OTC brands
 - Clear Eyes achieved #1 market share for the first time
 - Chloraseptic and Luden's gained 4.3 share points through strong digital programs
 - Little Remedies experienced strong consumption gains across all segments as a result of TV and digital marketing support



LUDEN'S Coody's MONISTAT Little Premedies & Opt Dramamine Courses of University University Conversion EVER Pade UDENS Coodys MONISTAT Guiden MONISTAT data Coody's MONISTAT Little Dramamine Company LittleEyes Gaviscon Debrox MONISTAT Little Providence Dramamine Company Little Eyes Gaviscon. Debrox (1999) (2000) S FABIRON Efferdent Cier Nix Pedia LUDEN'S Coody's MONISTAT' Little of Pedia Discourse Advised of Pedi Gaviscon. Debrox Hydratyje Chlorateptic Doctors FABIRON Efferdent clear Nix and Luces Concerts MONISTAT Remedies & Dramamine Company LittleEyes Gaviscon Debrox more Company Discont AT Little By Dramamine Compound W Little Eyes Gaviscon Debrox Hypers Gavages Doctors Drox Hydrayte Chloraseptic Doctor's FABIRON Efferdent Cear NDX Pade LUDENS CO. Goodys MCNISTO erdent clear Nix Pedia Luden's Coody's MONISTAT Little Remedies ? (P) Dramanne Hydrayre Chloraseptic Doctors FAB IRON Efferdent Certa Nix Con Condus MONISTAN Dramamine Company Little Eyes Gavision Debrax 15 Year in Review Compound Little Eyes Gaviscon. Debrox Hydravia Chloriseptic Doctors FAB IRON Effendent Car Nice and Doctors FAB IRON Efferdent Car Nix Car Ludens Goody's MONISTAT Littles & Cold le Eyes Gaviscon. Debrox: Hydral/e Chloraseptic @Doctor's FABIRON Efferdent Car NDX & Doors Con ody's MONISTAT Little of the Dramamine Company M Little Eyes Gaviscon Debrox Home and a company M ISTAT Remedies to Dramamine Composing W LittleEves Gaviscon. Debrox Inana Composing W /ISCOII. Debrox Hydral/@ Chloraseptic EDoctor3 FAB IRON Efferdent Car Nix & Lucens Concerned BIRON Efferdent Clear Nix Pade Luden's Coody's MONISTAT Remedier & CPI Domained Debrox Hydravie Chloraseptic EDoctors FABIRON Efferdent Creat Nix & Lupen's Co General Monte N Efferdent clear Nix Pedia Luden's Goody's MONISTAT Remedies & epi Dramanna W INTERVES GAVISCON. Debrox Norma Charagets Effectures Interventer



FY 15: Successful Execution Against Drivers of Long-Term Shareholder Value Creation


- 1
- Strong organic growth in Core OTC and international
- 2
- Portfolio strategy achieving desired results
- 3
- Margin expansion and efficiency gains allow for re-investment in A&P
- 4
- Consistent and increasing free cash flow
- 5
- Proven and repeatable M&A strategy

Well-Positioned for FY 16 and Beyond



Accelerated Core OTC Growth Trends


1



Data reflects retail dollar sales percentage growth versus prior period. **Prestige**Brands

FY 15 Core OTC Growth Broad Based Led by Largest Brands

% of Core OTC Portfolio with Consumption Growth in FY 15



Growth of Largest Brands Accelerating







1


Core OTC, includes Insight Pharmaceuticals. Source: IRI multi-outlet + C-Store, L-52 period ending March 22, 2015.

Portfolio Strategy Achieving Desired Results



Margin Expansion and Efficiency Gains Drives Increased A&P Investment






Dollar values in millions.

3



Increasing Our A&P Spend and Expanding Our Marketing Toolkit





3

Little Remedies Differentiation 3 Positions it well for Long-Term Success

ITTLE



New Products Driving Growth

Digital Execution Connecting with Moms



Effective solutions that are more natural with no artificial flavors or unnecessary ingredients





BabyCenter Integration



Post Photo / Video

Little Remedies

***** 171,706 mes

Website

Consumption +3.7% in L-26 Weeks; +8.5% in L-12 Weeks



FOR COUGHS

Source: IRI multi-outlet + C-Store, L-26 and L-12 periods ending March 22, 2015.

Detection Paofier, Just give II to 1 the one and based on the color if burns, you will know exactly why she i

FY 15 Learnings Are Positioning A \$100MM Brand for Growth



New Marketing Campaign

Letting consumers know that yeast infections are "No Big Deal" because there's Monistat

Developing HCP Relationship

Reinforcing strategy, messaging and communication with Health Care Professionals






3


Strong and Consistent Cash Flow Leads to Rapid Delevering and Increased M&A Capacity

4



Fourth

Proven and Repeatable M&A Strategy in Favorable Environment



Six Acquisitions Completed in Past Five Years for TEV of ~\$2BN



Dollar values in millions

M&A Has Established A Portfolio of Strong Brands Creating Attractive Category Platforms






M&A Has Established A Portfolio of Strong Brands Creating Attractive Category Platforms





5

Strategy Has Delivered Consistently Strong Financial Performance




Adjusted EBITDA⁽²⁾

Adjusted Free Cash Flow⁽²⁾



Adjusted EPS⁽²⁾





Dollar values in millions, except Adjusted EPS.


LUDEN'S Coody's MONISTAT Little Premedies & Opt Dramamine Courses of University University Conversion LUDENS Coordys MONISTAT Line of MONISTAT General Statement Coody's MONISTAT Little Dramamine Company LittleEyes Gaviscon Debrox MONISTAT Little Providence Dramamine Company Little Eyes Gaviscon. Debrox (1999) (2000) S FABIRON Efferdent Crear Nix Pedia LUDEN'S Coody's MONISTAT' Little of Pedia Periodice of Coody's MONISTAT' Little of Pedia Periodice of Coody's MONISTAT' Little of Pedia Gaviscon. Debrox Hydratyje Chlorateptic Doctors FABIRON Efferdent clear Nix and Luces Concerts MONISTAT Remedies & Dramamine Company LittleEyes Gaviscon Debrox more Company Discont AT Little By Dramamine Compound W Little Eyes Gaviscon Debrox Hypers Gavages Doctors Drox Hydrayte Chloraseptic Doctor's FABIRON Efferdent Cear NDX Pade LUDENS CO. Goodys MCNISTO erdent clear Nix Pedia Luden's Coody's MONISTAT Little Remedier & CPI Dramamme Hydralyte Chloraseptic Doctor's FABIRON Efferdent Coar Nix and Lucevis MONISTAT Promamine Concerned Little Eyes Gaviscon Debrox Financial Overview Compound U Little Eyes Gaviscon. Debrox Hydravia Chlorasepte Doctors FABIRON Efferdent Car Nor 200 Doctors FAB IRON Efferdent Car Nix Car Ludens Goody's MONISTAT Littles & Cold le Eyes Gaviscon. Debrox: Hydravie Chloraseptic Doctors FABIRON Efferdent Car NDX & Doctors Con ody's MONISTAT Little of the Dramamine Company M Little Eyes Gaviscon Debrox Home and a company M ISTAT Remedies & Dramamine Our Little Eyes Gaviscon. Debrox Human Chrame Elbour /ISCOII. Debrox Hydral/@ Chloraseptic EDoctors FABIRON Efferdent Gar Nix @ pupers con development BIRON Efferdent Creat Nix Pada Lupen's Coody's MONISTAT Remedian & CPU Diamander Debrox Hydravie Chloraseptic EDoctors FAB IRON Efferdent Creat Nix & Lucens Company House N Efferdent clear Nix Pedia Ludens Coody's MONISTAT Remedies & epi Dramanna The sume for the second descent the second descent

PrestigeBrands

Key Financial Results for Fourth Quarter Performance

Excellent overall financial performance in the quarter exceeded expectations

- Achieved organic growth of 2.4%⁽¹⁾ excluding the impact of foreign currency
- Revenue of \$190.0 million, an increase of 32.9%
- Adjusted EPS of \$0.47⁽²⁾, up 34.3%
- Adjusted Free Cash Flow growth of 45.0% to \$50.1 million⁽²⁾





Dollar values in millions, except per share data.

FY 15 Fourth Quarter and Fiscal Year Consolidated Financial Summary

- Q4 Revenue growth of +32.9%, or +34.5%⁽¹⁾ on a constant currency basis, Fiscal Year +20.4%
- Q4 Adjusted Gross Margin 57.9%⁽²⁾, highest in 6 quarters
- Q4 Adjusted EBITDA Margin of 36.1%⁽²⁾, Fiscal Year of 35.3%
- Q4 and FY Adjusted EPS growth ahead of Revenue growth, Q4 +34.3%⁽²⁾ and FY +21.6%

		3	Mon	ths End	ed	12 Months Ended								
	Μ	lar '15	Mar '14		% Chg		Mar '15		Mar '14		% Chg			
Total Revenue	\$	190.0	\$	143.1	32.9%		\$	714.6	\$	597.4	19.6%			
Adj. Gross Margin ⁽²⁾ % Margin		110.1 57.9%		78.8 55.1%	39.6%			408.4 57.2%		336.5 56.3%	21.4%			
A&P % Total Revenue		25.4 13.3%		17.5 12.2%	44.9%			99.7 13.9%		85.0 14.2%	17.3%			
Adj. G&A ⁽²⁾ % Total Revenue		16.1 8.5%		12.6 8.8%	27.5%			56.8 8.0%		47.4 7.9%	20.0%			
Adjusted EBITDA ⁽²⁾ % Margin	\$	68.6 36.1%	\$	48.7 34.0%	40.9%		\$	252.0 35.3%	\$	204.2 34.2%	23.4%			
Adjusted Net Income ⁽²⁾	\$	24.8	\$	18.6	33.1%		\$	98.0	\$	79.9	22.7%			
Adjusted Earnings Per Share ⁽²⁾	\$	0.47	\$	0.35	34.3%		\$	1.86	\$	1.53	21.6%			



Dollar values in millions, except per share data.

Exceptional Free Cash Flow Trends

Cash Flow											
	Q4	FY 15	Q4	FY 14	F	Y 15		FY 14			
Net Income - As Reported	\$	23.8	\$	16.0	\$	78.3	\$	72.6			
Depreciation & Amortization		5.8		3.3		17.7		13.5			
Other Non-Cash Operating Items		16.3		12.0		46.9		37.4			
Working Capital		6.3		(0.6)		13.3		(11.9)			
Operating Cash Flow ⁽⁷⁾	\$	52.1	\$	30.7	\$	156.3	\$	111.6			
Premium Payment on Notes		-		2.8		-		15.5			
Accelerated Interest Payments		-		1.2		-		4.7			
Additions to Property and Equipment		(2.4)		(0.1)		(6.1)		(2.8)			
Integration, Transition and Other Payments Associated with Acquisitions		0.4		-		13.6		0.5			
Adjusted Free Cash Flow ⁽²⁾	\$	50.1	\$	34.5	\$	163.7	\$	129.5			

Comments


Debt Profile & Financial Compliance:

Net Debt at 3/31/15 of \$1,572 million comprised of:

- Cash on hand of \$21 million
- \$944 million of term loan and revolver
- \$650 million of bonds
- Leverage ratio⁽³⁾ of ~5.2x
- Recent term loan refinancing continues to support rapid deleveraging



Dollar values in millions.






Staying the Strategic Course to continue **Shareholder Value Creation**


	 Continue category platform expansion/development
	 Capitalize on brand opportunities across channels of distribution
Brand	 Prioritize new product development and innovation
Building	 Little Remedies point of difference creates greatest long-term brand potential in pediatric portfolio moving forward
	 Power of Prestige's portfolio growing and delivering results
Insight	 New and significant Monistat advertising and Health Care Professional "HCP" investments launching in Q1
Growth Plan	 Expand Nix distribution and product offering
	 Prioritize and invest in feminine hygiene new product pipeline
	 Industry dynamics resulting in continued robust environment
M&A Strategy	 Big pharma portfolio rationalization continues
	 Committed to aggressive and disciplined M&A strategy
	Strong core OTC and international portfolio momentum going into FY 16
	 Consumer confidence improving
	 Retailers cautiously optimistic, bottom line focused
	Fx impact on top line continues
FY 16 Full	FY 16 outlook:
Year Outlook	 Revenue growth of +10% to +12% (including \$10MM negative Fx impact)
	 1H +20% to +23%, 2H +1.5% to +2.0%
	Adjusted EPS +10% to +13% (\$2.05 to \$2.10) ⁽⁸⁾
	 Free cash flow of \$175MM⁽⁹⁾ or more
	 Continued A&P investment in portfolio, Insight brands in particular
Prestige Brands	Fourth Quarter & FY 15 Results 24

Key Drivers of Long-Term Shareholder Value



PrestigeBrands

- Portfolio of recognizable brands in attractive consumer health industry
- Established expertise in brand building and product innovation
- Demonstrated ability to gain market share long-term
- Target Revenue contribution from Core OTC and International brands from ~78% to ~85%
- Efficient asset-lite model with best-in-class outsourced manufacturing and distribution partners
- Scalable operating platform key to Revenue expansion from \$300MM to \$800MM and beyond
- Business model enables gross margin expansion and G&A absorption
- Continued cost efficiencies expected with GM targeted at 60% and savings reinvested in A&P
- Strong and consistent cash flow driven by industry leading EBITDA margins, capital-lite business model and significant deferred tax assets
- Rapid deleveraging allows for expanded acquisition capacity and continued investment in brand building
- Non-core brands' role contributes to cash flow
- Debt repayment reduces cash interest expense and adds to EPS
- Demonstrated track record of 6 acquisitions during the past 5 years
- Effective consolidation platform positioned for consistent pipeline of opportunities
- Proven ability to source from varied sellers
- Fragmented industry and recent wave of acquisitions creates a robust pipeline



Appendix

- (1) Revenue Growth on a constant currency basis is a Non-GAAP financial measure and is reconciled to its most closely related GAAP financial measure in our earnings release in the "About Non-GAAP Financial Measures" section.
- (2) Adjusted Gross Margin, Adjusted G&A, Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Net Income, Adjusted EPS and Adjusted Free Cash Flow are Non-GAAP financial measures and are reconciled to their most closely related GAAP financial measures in our earnings release in the "About Non-GAAP Financial Measures" section, and are also reconciled on slides 29 through 32.
- (3) Leverage ratio reflects net debt / covenant defined EBITDA.
- (4) Pro forma Net Sales is projected for FY 15 as if Insight and Hydralyte were acquired on April 1, 2014.
- (5) Based on Company's organic long-term plan. Source: Company data.
- (6) Assumes max leverage of 5.75x and average EBITDA acquisition multiple consistent with previous acquisitions.
- (7) Operating cash flow is equal to GAAP net cash provided by operating activities.
- (8) Adjusted EPS for FY 16 is a projected Non-GAAP financial measure, is reconciled to projected GAAP EPS in our earnings release in the "About Non-GAAP Financial Measures" section and is calculated based on projected GAAP EPS of \$2.00 to \$2.05 plus \$0.05 of cost associated with term loan refinancing and CEO retirement totaling \$2.05 to \$2.10.
- (9) Adjusted Free Cash Flow for FY 16 is a projected Non-GAAP financial measure, is reconciled to projected GAAP Net Cash Provided by Operating Activities in our earnings release in the "About Non-GAAP Financial Measures" section and is calculated based on projected Net Cash Provided by Operating Activities of \$181 million less projected capital expenditures of \$6 million.



Reconciliation Schedules

Adjusted Gross Margin

	2010	2011	2012	2013	2014	2015
GAAP Gross Margin	\$ 150,494	\$ 167,273	\$ 224,118	\$ 343,737	\$ 335,551	\$ 406,223
Adjustments						
Inventory step up associated with acquisitions	-	7,273	1,795	23	577	2,225
Additional inventory transition and						
supplier costs associated with acquisitions	-	-	-	5,646	407	-
Total adjustments		7,273	1,795	5,669	984	2,225
Non-GAAP Adjusted Gross Margin	\$ 150,494	\$ 174,546	\$ 225,913	\$ 349,406	\$ 336,535	\$ 408,448
Non-GAAP Adjusted Gross Margin %	52.0%	52.4%	51.6%	56.3%	56.3%	57.2%

Adjusted G&A											
	2010	2011	2012	2013	2014	2015					
GAAP General and Administrative expenses	\$ 34,195	\$ 41,960	\$ 56,700	\$ 51,467	\$ 48,481	\$ 81,273					
Adjustments											
Legal and other professional fees associated with											
acquisitions	-	7,729	13,807	98	1,111	10,974					
Transition and other acquisition costs	-	-	3,588	5,811	-	13,473					
Unsolicited porposal costs	-	-	1,737	534	-	-					
Total adjustments	-	7,729	19,132	6,443	1,111	24,447					
Non-GAAP Adjusted G&A	\$ 34,195	\$ 34,231	\$ 37,568	\$ 45,024	\$ 47,370	\$ 56,826					
Non-GAAP Adjusted G&A %	11.8%	10.3%	8.6%	7.3%	7.9%	8.0%					



Dollar values in thousands.

Reconciliation Schedules Cont'd

Adjusted Net Income and Adjusted EPS												
	201	2010		2011		2	2013		2014		201	5
	Net Income	EPS	Net Income	EPS	Net Income	EPS	Net Income	EPS	Net Income	_		EPS
GAAP Net Income	\$32,115	\$0.64	\$29,220	\$0.58	\$37,212	\$0.73	\$65,505	\$1.27	\$72,615	\$1.39	\$78,260	\$1.49
Adjustments												
Income from discontinued ops.	-	-	(591)	(0.01)	-	-	-	-	-	-	-	-
Loss on sale of discontinued ops.	-	-	550	0.01	-	-	-	-	-	-	-	-
Incremental interest expense to												
finance Acquisition	-	-	800	0.02	-	-	-	-	-	-	-	-
Sales costs related to acquisitions	-	-	-	-	-	-	411	0.01	-	-	-	-
Inventory step up	-	-	7,273	0.14	1,795	0.04	23	-	577	0.01	2,225	0.04
Inventory related acquisition costs	-	-	-	-	-	-	220	-	407	0.01	-	-
Add'I supplier costs	-	-	-	-	-	-	5,426	0.11	-	-	-	-
Legal and other professional fees												
associated with acquisitions	-	-	7,729	0.15	13,807	0.27	98	-	1,111	0.02	10,974	0.21
Transition and other Acq costs	-	-	-	-	3,588	0.07	5,811	0.11	-	-	10,533	0.20
Stamp Duty	-	-	-	-	-	-	-	-	-	-	2,940	0.05
Unsolicited porposal costs	-	-	-	-	1,737	0.03	534	0.01	-	-	-	-
Loss on extinguishment of debt	2,656	0.05	300	0.01	5,409	0.11	1,443	0.03	18,286	0.35	-	-
Impairment of GW	-	-	-	-	-	-	-	-	-	-	-	-
Gain on settlement	-	-	-	-	(5,063)	(0.10)	-	-	-	-	-	-
Gain on sale of asset	-	-	-	-	-	-	-	-	-	-	(1,133)	(0.02
Accelerated amortization of debt												
discounts and debt issue costs	-	-	-	-	-	-	7,746	0.15	5,477	0.10	218	-
Tax impact on adjustments	(1,009)	(0.01)	(5,513)	(0.11)	(8,091)	(0.16)	(8,329)	(0.16)	(9,100)	(0.17)	(5,968)	(0.11
Impact of state tax adjustments	(352)	(0.01)	-	-	(237)	-	(1,741)	(0.03)	(9,465)	(0.18)	-	-
Total adjustments	1,295	0.03	10,548	0.21	12,945	0.26	11,642	0.23	7,293	0.14	19,789	0.37
Non-GAAP Adjusted Net Income												
and Non-GAAP Adjusted EPS	\$33,410	\$0.67	\$39,768	\$0.79	\$50,157	\$0.99	\$77,147	\$1.50	\$79,908	\$1.53	\$98,049	\$1.86



Dollar values in thousands, except per share data.

Reconciliation Schedules Cont'd

Adjusted EBITDA												
		2010	10 20		2012		2013		2014			2015
GAAP Net Income	\$	32,115	\$	29,220	\$	37,212	\$	65,505	\$	72,615	\$	78,260
Income from Disc Ops		112		(591)		-		-		-		-
Loss on sale of disc ops		(157)		550		-		-		-		-
Interest Expense, net		22,935		27,317		41,320		84,407		68,582		81,234
Provision for income taxes		20,664		19,349		23,945		40,529		29,133		49,198
Depreciation and amortization		10,001		9,876		10,734		13,235		13,486		17,740
Non-GAAP EBITDA		85,670		85,721		113,211		203,676		183,816		226,432
Sales costs related to acquisitions		-		-		-		411		-		-
Inventory step up		-		7,273		1,795		23		577		2,225
Inventory related acquisition costs		-		-		-		220		407		_,
Add'I supplier costs		-		-		-		5,426		-		-
Legal and other professional fees associated with								,				
acquisitions		-		7,729		13,807		98		1,111		10,974
Transition and other Acq costs		-		-		3,588		5,811		-		10,533
Stamp Duty		-		-		-		-		-		2,940
Unsolicited porposal costs		-		-		1,737		534		-		-
Loss on extinguishment of debt		2,656		300		5,409		1,443		18,286		-
Impairment of GW		-		-		-		-		-		-
Gain on settlement		-		-		(5,063)		-		-		-
Gain on sale of asset		-		-		-		-		-		(1,133)
Not shown in ER		-		-	_	-		-		-		-
Adjustments to EBITDA		2,656		15,302		21,273		13,966		20,381		25,539
Non-GAAP Adjusted EBITDA	\$	88,326	\$	101,023	\$	134,484	\$	217,642	\$	204,197	\$	251,971



Dollar values in thousands.

Reconciliation Schedules Cont'd

Adjusted Free Cash Flow

	2010	2011	2012	2013	2014	2015
GAAP Net Income	\$ 32,115	\$ 29,220	\$ 37,212	\$ 65,505	\$ 72,615	\$ 78,260
Adjustments						
Adjustments to reconcile net income to net cash						
provided by operating activities as shown in the						
statement of cash flows	31,137	26,095	35,674	59,497	50,912	64,668
Changes in operating assets and liabilities, net of effects from acquisitions as shown in the						
statement of cash flows	(3,825)	31,355	(5,434)	12,603	(11,945)	13,327
			· · _ · _ ·		· · · ·	
Total adjustments	27,312	57,450	30,240	72,100	38,967	77,995
GAAP Net cash provided by operating						
activities	59,427	86,670	67,452	137,605	111,582	156,255
Purchases of property and equipment	(673)	(655)	(606)	(10,268)	(2,764)	(6,101)
Non-GAAP Free Cash Flow	58,754	86,015	66,846	127,337	108,818	150,154
Premiuim payment on 2010 Senior Notes	-	-	-	-	15,527	-
Accelerated interest payments due to debt refinancing	_	-	-	-	4,675	-
Integration, transition and other payments					1,010	
associated with acquisitions	-	-	-	-	512	13,563
Total adjustments					20,714	13,563
Non-GAAP Adjusted Free Cash Flow	\$ 58,754	\$ 86,015	\$ 66,846	\$ 127,337	\$ 129,532	\$ 163,717



Dollar values in thousands.